CAM
AYTU icon

Crown Advisors Management’s AYTU BioPharma AYTU Stock Holding History

Crown Advisors Management’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$395K Buy
+145,000
New +$371K 0.26% 38

Other funds holding AYTU

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Crown Advisors Management's AYTU Position: Q1 2026 in Review

Crown Advisors Management opened a new position in AYTU BioPharma (AYTU) in Q1 2026: 145,000 shares worth $395K. The stake represents 0.26% of the portfolio and ranks #38 among its holdings.

37 funds tracked by Wall St. Rank hold AYTU as of Q1 2026.

  • Crown Advisors Management held 145,000 shares of AYTU BioPharma worth $395K as of Q1 2026.
  • AYTU BioPharma was a new Crown Advisors Management position in Q1 2026.
  • AYTU BioPharma made up 0.26% of Crown Advisors Management's portfolio in Q1 2026, its #38 holding.
  • 37 funds tracked by Wall St. Rank held AYTU BioPharma as of Q1 2026.

Based on Crown Advisors Management's 13F filing for Q1 2026, filed 8 May 2026.